BioCentury
ARTICLE | Clinical News

Biogen Idec dropping baminercept for RA

October 10, 2008 12:36 AM UTC

Biogen Idec (NASDAQ:BIIB) said it will discontinue development of baminercept for rheumatoid arthritis (RA) after top-line data showed the compound missed the primary and all second endpoints in the P...